These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1972238)

  • 1. Desferrioxamine versus erythropoietin for treatment of dialysis anaemia.
    Padovese P; Gallieni M; Galmozzi C; Brancaccio D
    Lancet; 1990 Jun; 335(8703):1465. PubMed ID: 1972238
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine improves anaemia in haemodialysis patients without aluminum or iron overload.
    Cuvelier R; Deceuninck P
    Nephrol Dial Transplant; 1988; 3(1):104. PubMed ID: 3132631
    [No Abstract]   [Full Text] [Related]  

  • 3. [Erythropoietin, aluminum and renal anemia].
    Schaefer M; Heidland A
    Dtsch Med Wochenschr; 1990 Jun; 115(22):878-9. PubMed ID: 2347300
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism.
    Grützmacher P; Ehmer B; Limbach J; Messinger D; Kulbe KD; Scigalla P
    Blood Purif; 1990; 8(5):279-84. PubMed ID: 2091687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of desferrioxamine on anaemia of haemodialysis patients.
    Felipe C; Rivera M; Orofino L; Matesanz R; Ortuño J
    Nephrol Dial Transplant; 1988; 3(1):105-106. PubMed ID: 3132633
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine, anaemia, and haemodialysis.
    Lancet; 1988 Jun; 1(8599):1405-6. PubMed ID: 2898087
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment.
    Donnelly SM; Smith EK
    Am J Kidney Dis; 1990 Nov; 16(5):487-90. PubMed ID: 2239943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
    Yaqoob M; Ahmad R; McClelland P; Shivakumar KA; Sallomi DF; Fahal IH; Roberts NB; Helliwell T
    Postgrad Med J; 1993 Feb; 69(808):124-8. PubMed ID: 8506193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aluminum and iron deposition in dialysis patients].
    Kurihara S; Marumo F
    Nihon Rinsho; 1992 Jan; 50 Suppl():905-10. PubMed ID: 1578787
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.
    Piazza V; Villa G; Galli F; Segagni S; Bovio G; Poggio F; Picardi L; Salvadeo A
    Nephron; 1992; 61(1):54-7. PubMed ID: 1528341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microcytic anemia in dialysis patients.
    Grossman SD; Smith LE
    Am J Kidney Dis; 1988 Apr; 11(4):362. PubMed ID: 3354574
    [No Abstract]   [Full Text] [Related]  

  • 12. [Does aluminum affect the effectiveness of human recombinant erythropoietin in the treatment of anemia in dialyzed patients?].
    Sulková S; Laurincová Z; Kvasnicka J
    Cas Lek Cesk; 1990 Jan; 129(4):113-5. PubMed ID: 2331725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desferrioxamine does not improve aluminium-unrelated anaemia of haemodialysis.
    Basile C; Scatizzi A
    Nephrol Dial Transplant; 1988; 3(3):355. PubMed ID: 3140114
    [No Abstract]   [Full Text] [Related]  

  • 14. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When should we start erythropoietin therapy?
    O'Riordan E; Foley RN
    Nephrol Dial Transplant; 2001 May; 16(5):891-2. PubMed ID: 11328891
    [No Abstract]   [Full Text] [Related]  

  • 16. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
    Altmann P; Plowman D; Marsh F; Cunningham J
    Lancet; 1988 May; 1(8593):1012-5. PubMed ID: 2896867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

  • 19. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 20. Immobilized desferrioxamine (DFO) for the extracorporeal removal of aluminum.
    Anthone S; Ambrus CM; Horvath C; Kalghatgi K
    ASAIO Trans; 1987; 33(3):744-8. PubMed ID: 3676012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.